Tech Company Inital Public Offerings
Athira Pharma IPO
Headquartered in Seattle, Athira Pharma is now a public company.
Management says it will use the net proceeds from the IPO as follows:approximately $75.0 million to fund the clinical development of ATH-1017 including the LIFT-AD trial and the ACT-AD P300 Phase 2 trial for the treatment of mild-to-moderate Alzheimer's disease;approximately $20.0 million to fund our planned Phase 2 trial of ATH-1017 for the treatment of Parkinson's disease dementia;approximately $30.0 million to fund our IND-enabling studies of ATH-1019 for the treatment of neuropsychiatric indications and ATH-1018 for the treatment of neuropathy; andthe remainder for our other research and development activities, as well as for working capital and other general corporate purposes.
4000 Mason Rd. 300 Box 352141
Seattle, WA 98195
Seattle, WA 98195
Athira Pharma (Nasdaq: ATHA) is a drug development company striving to improve human health by advancing new therapies for neurodegenerative diseases like Alzheimer's and Parkinson's. Our innovative approach is focused on turning brain degeneration into regeneration, achieved by re-establishing lost connections and restoring lost function.
Email & Social
Browse more venture capital transactions:
Prev: 9/17/2020: Sun Genomics venture capital transaction
Next: 9/18/2020: Palleon Pharmaceuticals venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs